Drug Trial Radar · NCT01685424
Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)
Last checked: Nov 19, 2026Latest source record: Feb 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79,189
Actual
Start
Jun 30, 2006
Primary completion
Mar 1, 2015
Study completion Mar 1, 2015
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 14, 2012
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency (MHRA) General Practice Research Database (GPRD).
Conditions
- Osteoarthritis
- Rheumatoid Arthritis
- Ankylosing Spondylitis
- Gout
- Arthritis
Interventions
EtoricoxibDrug
As per routine clinical practice in the United Kingdom
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose of Initial Etoricoxib PrescriptionTime frame: At first prescription (during a time period up to 13.75 years)
- Duration of Initial Etoricoxib PrescriptionTime frame: At first prescription (during a time period up to 13.75 years)
- Participant's Baseline Characteristics (Demographics and Medical)Time frame: At first prescription (during a time period up to 13.75 years)
- Incidence of Adverse Events of Special Interest Among Etoricoxib UsersTime frame: During a time period up to 13.75 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.